Lenalidomide Teva (Lenalidomide)

Lenalidomide is used in the management of hematologic malignancies, targeting abnormal plasma cells and myeloid clones.

• Multiple Myeloma: reduces disease progression and improves survival in patients with relapsed or refractory disease.
• Myelodysplastic Syndromes with del(5q): induces transfusion independence and cytogenetic remission in eligible patients.
• Mantle Cell Lymphoma: contributes to disease control as part of combination therapy in relapsed or refractory cases.

• Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering substrate specificity. This leads to ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos, resulting in reduced proliferation of malignant cells, inhibition of angiogenesis, and enhanced immune‑mediated tumor cell clearance. The drug also modulates cytokine production, increasing T‑cell and NK‑cell activity, which further contributes to its anti‑tumor efficacy.

Lenalidomide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Fatigue: persistent tiredness affecting daily activities.
• Diarrhea: loose stools that may require fluid replacement.
• Nausea: feeling of sickness that can be mild to moderate.
• Rash: skin irritation or redness.
• Constipation: difficulty passing stools.
• Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects

• Thromboembolic events: deep vein thrombosis or pulmonary embolism.
• Severe neutropenia: markedly reduced white blood cell count increasing infection risk.
• Severe thrombocytopenia: low platelet count leading to bleeding.
• Secondary primary malignancies: emergence of new cancers.
• Hepatotoxicity: liver enzyme elevations or liver injury.

Before initiating lenalidomide therapy, several precautions should be considered to ensure patient safety.

• Pregnancy risk: contraindicated in pregnancy (Category X); effective contraception required for women of childbearing potential.
• Thromboembolic risk: assess for clotting risk and consider prophylactic anticoagulation.
• Hematologic monitoring: perform regular complete blood counts to detect neutropenia or thrombocytopenia.
• Renal function: evaluate kidney function and adjust dosing in impairment.
• Infection risk: monitor for signs of infection and manage promptly.
• Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Lenalidomide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers: may reduce lenalidomide exposure; avoid co‑administration.
• Anticoagulants (warfarin, DOACs): increased risk of bleeding; close monitoring required.

Moderate Interactions (Monitor Closely)

• Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity.
• Vaccines: live vaccines should be avoided due to immunomodulatory effects.
• P-glycoprotein inhibitors: may increase plasma levels of lenalidomide.
• NSAIDs: may exacerbate thrombocytopenia risk.